A fundamental shift in how medicine conceptualizes one of the most common hormonal disorders affecting women promises to reshape diagnosis, treatment, and research trajectories for millions worldwide. The condition affecting one in eight women globally now has a name that accurately reflects its complex pathophysiology rather than perpetuating misleading terminology.
Through an unprecedented global consensus process involving 56 leading organizations and input from 14,360 patients and healthcare professionals across all world regions, researchers have formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). The new designation eliminates the misleading reference to ovarian cysts, which are neither universally present nor causative, while explicitly acknowledging the condition's multisystem endocrine disruptions and metabolic dysfunction that extend far beyond reproductive organs.
This nomenclature evolution addresses decades of clinical confusion where the "cyst" terminology led to fragmented care, delayed diagnoses, and research limitations. The condition involves complex interactions between insulin resistance, androgen excess, and reproductive dysfunction—none of which the previous name captured. The systematic renaming process, employing modified Delphi methods and nominal group techniques, prioritized scientific accuracy over convenience, marking a rare instance where medical consensus actively corrected historical terminology rather than preserving tradition. While implementation will require coordinated efforts across medical education, clinical guidelines, and patient advocacy, the change represents a paradigm shift toward precision medicine approaches that acknowledge PMOS as the complex endocrine-metabolic disorder it truly is, potentially improving both clinical outcomes and research focus.